IL5RA and eosinophilic esophagitis: Monoclonal antibodies against the IL-5 pathway, particularly mepolizumab, achieve dramatic eosinophil reduction in IL5RA-associated eosinophilic esophagitis by interrupting this critical cytokine-receptor axis [41–43].